前沿速览041期| CAR-T治B淋 前沿览新知
01
4-1BB共刺激域CD19 CAR-NK细胞治疗复发/难治性大B细胞淋巴瘤的安全性与可行性：一项I期临床试验
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial
第一作者：Lei W
Nat Cancer (IF=23.5). 2025 Apr 18.
全文网址：https://www.nature.com/articles/s43018-025-00940-3
02
CAR-T细胞疗法获批与美国弥漫大 B 细胞淋巴瘤患者预后相关性分析
Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States
第一作者：Vaughn JL
Biomark Res (IF=9.5). 2025 Apr 24;13(1):64.
全文网址：https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-025-00780-4
03
淋巴瘤患者CAR-T细胞治疗后的低镁血症与免疫功能障碍及生存率降低的相关性分析
Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival
第一作者：Gile JJ
Exp Hematol Oncol (IF=9.4). 2025 Apr 30;14(1):63.
全文网址：https://ehoonline.biomedcentral.com/articles/10.1186/s40164-025-00623-w
04
半定量PET参数在CAR-T细胞治疗后1个月和3个月的淋巴瘤预后评估中的价值：一项前瞻性单中心研究
Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study
第一作者：Farolfi A
J Nucl Med (IF=9.1). 2025 Apr 17:jnumed.125.269670.
全文网址：https://jnm.snmjournals.org/content/early/2025/04/17/jnumed.125.269670.long
05
复发/难治性大B细胞淋巴瘤患者CD19 CAR-T治疗后基于应答调整泽布替尼联合替雷利珠单抗方案作为CAR-T治疗的潜在增效策略：一项回顾性观察研究
Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study
第一作者：Shen R
Clin Transl Med (IF=7.9). 2025 Apr;15(4):e70310.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12017895/
06
Lisocabtagene maraleucel治疗无意向接受造血干细胞移植的复发/难治性大B细胞淋巴瘤患者：PILOT II期研究的最终结果
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study
第一作者：Sehgal A
Blood Adv (IF=7.4). 2025 Apr 30:bloodadvances.2024015262.
全文网址：https://ashpublications.org/bloodadvances/article-lookup/doi/10.1182/bloodadvances.2024015262
07
CAR-T细胞治疗失败后，双特异性抗体治疗复发/难治性大B细胞淋巴瘤的疗效
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
第一作者：Shumilov E
Blood Adv (IF=7.4). 2025 Apr 16:bloodadvances.2024015719.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024015719/536732/Outcomes-of-bispecific-antibody-therapy-after-CAR
08
脑电图可作为CD19 CAR-T细胞治疗后神经毒性预测的生物标志物
EEG as a predictive biomarker of neurotoxicity in anti-CD19 CAR T-cell therapy
第一作者：Pondrelli F
J Neurol (IF=4.8). 2025 Apr 25;272(5):360.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12031834/
09
CAR-T细胞疗法在改善复发/难治性弥漫大B细胞淋巴瘤疗效中的作用
The Improving Outcomes in Relapsed-Refractory Diffuse Large B Cell Lymphoma: The Role of CAR T-Cell Therapy
第一作者：Milunović V
Curr Treat Options Oncol (IF=3.8). 2025 Apr 28.
全文网址：https://link.springer.com/article/10.1007/s11864-025-01305-9
10
全脑放疗联合CAR-T细胞治疗复发/难治性中枢神经系统B细胞淋巴瘤
Whole brain radiotherapy combined with CART-cell therapy for relapsed/refractory central nervous system B-cell lymphoma
第一作者：Shi H
Ann Hematol (IF=3.0). 2025 Apr;104(4):2495-2505.
全文网址：https://link.springer.com/article/10.1007/s00277-025-06378-y
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.5-6 valid until 2027.5
供稿与审核：临床开发与医学部